Lutetium 177Lu-Edotreotide Versus Best Standard of Care in Well-differentiated Aggressive Grade-2 and Grade-3 GastroEnteroPancreatic NeuroEndocrine Tumors (GEP-NETs) - COMPOSE
Clinical trial NCT04919226 · ACTIVE_NOT_RECRUITING
Trial details
- NCT number
- NCT04919226
- Sponsor
- ITM Solucin GmbH
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- Phase 3
- Study type
- INTERVENTIONAL
- Start date
- 2021-12-21
- Primary completion
- 2027-06-01
- Enrollment
- 259
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.